Diagnostic tumor marker of asbestos-related mesothelioma

Environmental Health and Preventive Medicine

Volumn 13, Issue 2, 2008, Pages 71-74

  Hino, Okio ^a   Maeda, Masahiro ^b  

^a JUNTENDO UNIVERSITY   (Japan)

^b Immuno Biological Laboratories Co Ltd   (Japan)

Author keywords

Asbestos; ELISA; ERC mesothelin MPF; Mesothelioma; Tumor marker

Indexed keywords

ASBESTOS; GENE PRODUCT; MESOTHELIN; MONOCLONAL ANTIBODY; N ERC MESOTHELIN; PROTEIN; SOLUBLE MESOTHELIN RELATED PROTEIN; TUMOR MARKER;

AMINO TERMINAL SEQUENCE; CANCER DIAGNOSIS; CARBOXY TERMINAL SEQUENCE; CONFERENCE PAPER; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPRESSED IN RENAL CARCINOMA GENE; GENE; GENE SEQUENCE; HUMAN; INCUBATION TIME; MESOTHELIN GENE; MESOTHELIOMA; NONHUMAN; OCCUPATIONAL EXPOSURE; PLEURISY; SEQUENCE HOMOLOGY;

RATTUS;

EID: 49549101979     PISSN: 1342078X     EISSN: 13474715     Source Type: Journal    
DOI: 10.1007/s12199-007-0014-9     Document Type: Conference Paper

References (20)

1. Eker R, Mossige JA. A dominant gene for renal adenomas in the rat. Nature. 1961;189:858-9.
2. Hino O, Kobayashi E, Nishizawa M, et al. Renal carcinogenesis in the Eker rat. J Cancer Res Clin Oncol. 1995;121:602-5.
3. Yamashita Y, Yokoyama M, Kobayashi E, Takai S, Hino O. Mapping and determination of the cDNA sequence of the Erc gene preferentially expressed in renal cell carcinoma in the Tsc2 gene mutant (Eker) rat model. Biochem Biophys Res Commun. 2000;275:134-40.
4. Yamaguchi N, Hattori K, Oh-eda M, Kojima T, Imai N, Ochi N. A novel cytokine exhibiting megakaryocyte potentiating activity from a human pancreatic tumor cell line HPC-Y5. J Biol Chem. 1994;269:805-8.
5. Kojima T, Oh-eda M, Hattori K, et al. Molecular cloning and expression of megakaryocyte potentiating factor cDNA. J Biol Chem. 1995;270:21984-90.
6. Nakaishi M, Kajino K, Ikesue M, et al. Establishment of the enzyme-linked immunosorbent assay system to detect the amino terminal secretory form of rat Erc/Mesothelin. Cancer Sci. 2007;98:659-64.
7. Shiomi K, Miyamoto H, Segawa T, et al. A novel ELISA system for detection of a 'N-ERC/Mesothelin' in the sera of mesothelioma patients. Cancer Sci. 2006;97:928-32.
8. Maeda M, Hino O. Molecular tumor markers for asbestos-related mesothelioma: serum diagnostic markers. Pathol Int. 2006;56:649-54.
9. Maeda M, Hino O. Blood test for asbestos-related mesothelioma. Oncology. 2006;71:26-31.
10. Hino O, Shiomi K, Maeda M. Diagnostic biomarker of asbestos-related mesothelioma: example of translational research. Cancer Sci. 2007;98:1147-51.
11. Chang K, Pastan I. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci USA. 1996;93:136-40.
12. Chang K, Pai LH, Pass H, et al. Monoclonal antibody K1 reacts with epithelial mesothelioma but not with lung adenocarcinoma. Am J Surg Pathol. 1992;16:259-68.
13. Onda M, Nagata S, Ho M, et al. Megakaryocyte potentiation factor cleaved from mesothelin precursor is a useful tumor marker in the serum of patients with mesothelioma. Clin Cancer Res. 2006;12:4225-31.
14. Robinson BW, Creaney J, Lake R, et al. Mesothelin-family proteins and diagnosis of mesothelioma. Lancet. 2003;362:1612-16.
15. Robinson BW, Creaney J, Lake R, et al. Soluble mesothelin related protein: a blood test for mesothelioma. Lung Cancer. 2005;49:S109-11.
16. Scherpereel A, Grigoriu B, Conti M, et al. Soluble mesothelin related peptides in the diagnosis of malignant pleural mesothelioma. Am J Respir Crit Care Med. 2006;173:1155-60.
17. Beyer HL, Geschwindt RD, Glover CL, et al. MESOMARKTM: a potential test for malignant pleural mesothelioma. Clin Chem. 2007;53:666-72.
18. Hassan R, Bera T, Pastan I. Mesothelin: a new target for immunotherapy. Clin Cancer Res. 2004;10:3937-42.
19. Onda M, Willingham M, Nagata S, et al. New monoclonal antibodies to mesothelin useful for immunohistochemistry, fluorescence-activated cell sorting, Western blotting, and ELISA. Clin Cancer Res. 2005;11:5840-6.
20. Hassan R, Remaley AT, Sampson ML, et al. Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer. Clin Cancer Res. 2006;12:447-53.